Previous Close | 221.75 |
Open | 221.85 |
Bid | 217.40 x 800 |
Ask | 218.02 x 900 |
Day's Range | 215.81 - 222.60 |
52 Week Range | 118.18 - 280.62 |
Volume | |
Avg. Volume | 234,295 |
Market Cap | 48.681B |
Beta (5Y Monthly) | 0.76 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., March 30, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the appointment of Julius Pryor III as its first Global Head of Diversity and Health Equity, effective immediately.
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., March 21, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, is entering a new phase as it continues to build its U.S. presence. The company announced today that the last piece of structural steel will be laid at its Hopewell, NJ campus today. This new facility will provide state-of-the-art commercial-stage U.S. biologic pharmaceutical manufacturing, late-stage research and clinical development capabilities tha
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., February 27, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results for the fourth quarter and full year 2022, recent business highlights, and upcoming milestones.